Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...
Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with CURE that the Food and Drug Administration (FDA) removal of primary central ...
RICHMOND - A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific ...
Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.
The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
A new UNC study finds that a chemical derived from ashwagandha disrupts viral and cancer processes that make B-cell lymphomas ...
For some people, treating follicular lymphoma involves active surveillance until severe symptoms develop. For others, chemoimmunotherapy, radiation therapy, or targeted treatments may be necessary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results